This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kemp, Z. Articles by Tomlinson, I. Search for Related Content PubMed PubMed Citation Articles by Kemp, Z. Articles by Tomlinson, I.

CDC4 Mutations Occur in a Subset of Colorectal Cancers but Are Not Predicted to Cause Loss of Function and Are Not Associated with Chromosomal Instability

¹ Molecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom; ² Department of Colorectal Surgery, John Radcliffe Hospital, Oxford, United Kingdom; ³ Histopathology Department, St. Mark's and Northwick Park Hospitals; ⁴ Colorectal Cancer Unit, Cancer Research UK, St. Mark's Hospital, Harrow, United Kingdom; and ⁵ Histopathology Department, University of Nottingham, The Queen's Medical Centre, Nottingham, United Kingdom

Requests for reprints: Ian Tomlinson, Molecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, United Kingdom. Phone: 44-0-207-269-2884; Fax: 440-207-269-3093; E-mail: ian.tomlinson{at}cancer.org.uk.

CDC4/FBXW7 is part of a ubiquitin ligase complex which targets molecules such as cyclin E, c-myc, and c-jun for destruction. CDC4 mutations occur in several cancer types and are best described in colorectal tumors. Knockout of CDC4 in vitro in colorectal cancer cells causes changes suggestive of chromosomal instability (CIN). In p53^+/– mice, radiation-induced lymphomas show deletion or mutation of one copy of CDC4 and knockdown of CDC4 leads to increased aneuploidy in mouse fibroblasts. We screened 244 colorectal tumors and 40 cell lines for CDC4 mutations and allelic loss. Six percent (18 of 284) of tumors, including near-diploid (CIN–) lesions, harbored CDC4 mutations and there was no association between mutation and CIN (polyploidy). The CDC4 mutation spectrum in colorectal tumors was heavily biased towards C:G>T:A changes, either missense mutations at critical arginine residues or nonsense changes in the 5' half of the gene. The reasons for this odd mutation spectrum were unclear but C:G>T:A changes were not found more often than expected at APC, K-ras, or p53 in the same tumors and we found no specific defects in DNA repair to account for the observations. No colorectal tumor was found to carry two CDC4 mutations predicted to abolish protein function; partial loss of CDC4 function may therefore cause tumorigenesis. The in vitro studies, therefore, did not assess the functional effects of mutant alleles which are found in vivo. CDC4 mutations may be selected primarily to drive progression through the cell cycle although CIN might be an important secondary effect in some cancers. (Cancer Res 2005; 65(24): 11361-6)

This article has been cited by other articles:

				J. McLellan, N. O'Neil, S. Tarailo, J. Stoepel, J. Bryan, A. Rose, and P. Hieter Synthetic Lethal Genetic Interactions That Decrease Somatic Cell Proliferation in Caenorhabditis elegans Identify the Alternative RFCCTF18 as a Candidate Cancer Drug Target Mol. Biol. Cell, December 15, 2009; 20(24): 5306 - 5313. [Abstract] [Full Text] [PDF]

				J.-H. Mao, I.-J. Kim, D. Wu, J. Climent, H. C. Kang, R. DelRosario, and A. Balmain FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression Science, September 12, 2008; 321(5895): 1499 - 1502. [Abstract] [Full Text] [PDF]

				Y. Suehiro, T. Okada, T. Okada, K. Anno, N. Okayama, K. Ueno, M. Hiura, M. Nakamura, T. Kondo, A. Oga, et al. Aneuploidy Predicts Outcome in Patients with Endometrial Carcinoma and Is Related to Lack of CDH13 Hypermethylation Clin. Cancer Res., June 1, 2008; 14(11): 3354 - 3361. [Abstract] [Full Text] [PDF]

				S. Akhoondi, D. Sun, N. von der Lehr, S. Apostolidou, K. Klotz, A. Maljukova, D. Cepeda, H. Fiegl, D. Dofou, C. Marth, et al. FBXW7/hCDC4 Is a General Tumor Suppressor in Human Cancer Cancer Res., October 1, 2007; 67(19): 9006 - 9012. [Abstract] [Full Text] [PDF]

				B. J. Thompson, S. Buonamici, M. L. Sulis, T. Palomero, T. Vilimas, G. Basso, A. Ferrando, and I. Aifantis The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia J. Exp. Med., August 6, 2007; 204(8): 1825 - 1835. [Abstract] [Full Text] [PDF]

				J. O'Neil, J. Grim, P. Strack, S. Rao, D. Tibbitts, C. Winter, J. Hardwick, M. Welcker, J. P. Meijerink, R. Pieters, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to {gamma}-secretase inhibitors J. Exp. Med., August 6, 2007; 204(8): 1813 - 1824. [Abstract] [Full Text] [PDF]

				W. Zhang and D. M. Koepp Fbw7 Isoform Interaction Contributes to Cyclin E Proteolysis Mol. Cancer Res., December 1, 2006; 4(12): 935 - 943. [Abstract] [Full Text] [PDF]